Astec LifeSciences Limited
The Company is into manufacturing of agrochemical active ingredients (technical), bulk and formulations, intermediate products and it sells its products in India as well as exports them to approximately 24 countries.Astec also has undertaken a number of custom synthesis projects, for its clients in Europe, Japan and the US. It is present only in business to business sale (B2B).
What Astec files
- Others215
- Important54
- Updates30
- Board Meeting29
- Dividend/Bonus12
- QIP/Rights/Pref.8
Astec LifeSciences has clarified regarding recent significant stock price movements, confirming that it has consistently disclosed all necessary events and information to the stock exchanges. The company has explicitly confirmed that there are no undisclosed developments, pending events, or material information requiring mandatory disclosure at this time. Management remains committed...
Astec LifeSciences Limited has clarified that it has disclosed all necessary information impacting share prices to the stock exchanges as required. Addressing a recent significant increase in trading volume, the company has confirmed that no undisclosed events or pending developments exist that require mandatory disclosure. Management assures shareholders that the...
Astec LifeSciences saw improved FY26 financials: Total Income rose to ₹453.22 Cr, losses narrowed to ₹80.88 Cr, and EBITDA turned positive at ₹0.54 Cr. Strong domestic sales and CDMO growth contributed. A rights issue of ₹249.35 Cr enlarged its capital base, supporting R&D and sustainability initiatives.
Astec LifeSciences reports Q1 FY27 consolidated total income of ₹84.3 Cr, down 8%. The company achieved EBITDA breakeven (₹0.1 Cr) from a ₹10.5 Cr loss, driven by improved margins and capacity utilization. Enterprise Products revenue grew 42%, while CDMO fell 42% against a high base.
Astec LifeSciences reported Q1FY27 consolidated total income of ₹84.3 Cr, down 8%. Despite lower revenue, the company achieved EBITDA breakeven at ₹0.1 Cr, reducing loss to ₹18.7 Cr. This improvement was driven by a favorable product mix and enhanced capacity utilization.